Sitravatinib – 25 mg

Brand:
Cayman
CAS:
1123837-84-2
Storage:
-20
UN-No:
Non-Hazardous - /

Sitravatinib is a multi-kinase inhibitor.{53144} It inhibits 35 kinases (IC50s = 0.5-5,550 nM) in a panel of 55 receptor tyrosine kinases (RTKs). Sitravatinib reduces proliferation of A-673, LPS141, MPNST, DDLS, and Saos-2 cancer cells (IC50s = 1,750, 340.1, 705.7, 266, and 1,830 nM, respectively) and decreases phosphorylation of insulin-like growth factor 1 receptor (IGF1-R), PDGFRβ, and Akt in these same cells when used at concentrations ranging from 62.5 to 4,000 nM. It decreases tumor growth in LPS141 and MPNST mouse xenograft models when administered at a dose of 15 mg/kg per day.  

 

Available on backorder

SKU: 27338 - 25 mg Category:

Description

A multi-kinase inhibitor; inhibits 35 kinases (IC50s = 0.5-4,098 nM) in a panel of 55 RTKs; reduces proliferation in various cancer cells (IC50s = 340.1-1,830 nM) and decreases phosphorylation of IGF1-R, PDGFRβ, and Akt at 62.5-4,000 nM; decreases tumor growth in LPS141 and MPNST mouse xenograft models at 15 mg/kg per day


Formal name: N-[3-fluoro-4-[[2-[5-[[(2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-N’-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

Synonyms:  MGCD-516

Molecular weight: 629.7

CAS: 1123837-84-2

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling